Skip to content
Menu

JP Morgan Maintains Overweight on Enanta Pharmaceuticals, Lowers Price Target to $17

Benzinga Newsdesk 55 minutes ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Anupam Rama maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Overweight and lowers the price target from $19 to $17.

JP Morgan analyst Anupam Rama maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Overweight and lowers the price target from $19 to $17.

Read at benzinga.com